Placement Success: Dewpoint Therapeutics

Congratulations to Dewpoint Therapeutics on the appointment of Dr. Karl Hsu, M.D. as Head of Development. Karl is a seasoned physician-scientist with over 20 years of experience in clinical drug development, specializing in oncology and hematology. GSS is privileged to have supported Dewpoint Therapeutics in their mission to assemble the most extraordinary talent in condensate science to brave a path in developing a new generation of medicines. 

Clinical Development

Karl Hsu, M.D.

Dewpoint Therapeutics

Karl Hsu leads Development at Dewpoint Therapeutics. A physician-scientist with more than 20 years in clinical drug development, he specializes in oncology and hematology and has co-authored over 30 peer-reviewed publications.

His prior roles include Senior Vice President of Clinical Research and Early Development at Zai Lab, global development leadership roles at Sanofi (including early oncology development and the early work on isatuximab), and early development leadership at Merck Research Laboratories. He earned his M.D. at the Perelman School of Medicine at the University of Pennsylvania.

Read the full profile

Source: Dewpoint Therapeutics.